Dyslipidemiat, näytönastekatsausten kirjallisuusviitteet

Kirjallisuutta

1. Collins R, Reith C, Emberson J, ym. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388(10059):2532-2561 «PMID: 27616593»PubMed
2. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, ym. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81 «PMID: 21067804»PubMed
3. Taylor F, Huffman MD, Macedo AF, ym. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;2013(1):CD004816 «PMID: 23440795»PubMed
4. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, ym. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380(9841):581-90 «PMID: 22607822»PubMed
5. Jakob T, Nordmann AJ, Schandelmaier S, ym. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2016;11(11):CD009753 «PMID: 27849333»PubMed
6. Wang D, Liu B, Tao W, ym. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;2015(10):CD009580 «PMID: 26497361»PubMed
7. Kim KA, Kim NJ, Choo EH. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. Eur J Prev Cardiol 2024;31(3):291-301 «PMID: 37855457»PubMed
8. Wiegman A, Hutten BA, de Groot E, ym. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292(3):331-7 «PMID: 15265847»PubMed
9. Rodenburg J, Vissers MN, Wiegman A, ym. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116(6):664-8 «PMID: 17664376»PubMed
10. Luirink IK, Wiegman A, Kusters DM, ym. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019;381(16):1547-1556 «PMID: 31618540»PubMed
11. Braamskamp MJAM, Langslet G, McCrindle BW, ym. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation 2017;136(4):359-366 «PMID: 28592434»PubMed
12. Vuorio A, Kuoppala J, Kovanen PT, ym. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019;2019(11): «PMID: 31696945»PubMed
13. Joyce NR, Zachariah JP, Eaton CB, ym. Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. Acad Pediatr 2017;17(5):515-522 «PMID: 28232259»PubMed
14. Llewellyn A, Simmonds M, Marshall D, ym. Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials. Atherosclerosis 2025;401():118598 «PMID: 39343641»PubMed
15. Koskinen P, Mänttäri M, Manninen V, ym. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15(7):820-5 «PMID: 1516498»PubMed
16. Rubins HB, Robins SJ, Collins D, ym. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162(22):2597-604 «PMID: 12456232»PubMed
17. . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-10 «PMID: 11289345»PubMed
18. Ritland N, Melbye H. [C-reactive protein, SR and white blood cell count in acute lower respiratory tract diseases. The usefulness of blood tests in diagnosis of pneumonia]. Tidsskr Nor Laegeforen 1991;111(18):2249-52 «PMID: 1896976»PubMed
19. ACCORD Study Group, Ginsberg HN, Elam MB, ym. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74 «PMID: 20228404»PubMed
20. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010;141(2):157-66 «PMID: 19232762»PubMed
21. Bruckert E, Labreuche J, Deplanque D, ym. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011;57(2):267-72 «PMID: 21052016»PubMed
22. Das Pradhan A, Glynn RJ, Fruchart JC, ym. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022;387(21):1923-1934 «PMID: 36342113»PubMed
23. Elam MB, Ginsberg HN, Lovato LC, ym. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol 2017;2(4):370-380 «PMID: 28030716»PubMed
24. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393(10170):407-415 «PMID: 30712900»PubMed
25. Strandberg TE, Benetos A. Hippocratic considerations about statin treatment for patients over 75 years of age. Eur Geriatr Med 2025;16(2):393-395 «PMID: 39932631»PubMed
26. Zoungas S, Curtis A, Spark S, ym. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open 2023;13(4):e069915 «PMID: 37012015»PubMed
27. Joseph J, Pajewski NM, Dolor RJ, ym. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc 2023;71(6):1701-1713 «PMID: 37082807»PubMed
28. Amarenco P, Bogousslavsky J, Callahan A 3rd, ym. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):549-59 «PMID: 16899775»PubMed
29. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012;43(8):2149-56 «PMID: 22588266»PubMed
30. Pandit AK, Kumar P, Kumar A, ym. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand 2016;134(1):22-8 «PMID: 26647879»PubMed
31. Judge C, Ruttledge S, Costello M, ym. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. J Stroke Cerebrovasc Dis 2019;28(6):1703-1709 «PMID: 30878368»PubMed
32. Winardi W, Moi SH, Winardi T, ym. Nationwide Big Data Analysis of Statin Use and Intracerebral Hemorrhage Risk in Acute Ischemic Stroke Patients in Taiwan. Medicina (Kaunas) 2024;60(6): «PMID: 38929556»PubMed
33. León H, Shibata MC, Sivakumaran S, ym. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008;337():a2931 «PMID: 19106137»PubMed
34. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, ym. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr 2012;107 Suppl 2():S201-13 «PMID: 22591894»PubMed
35. . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354(9177):447-55 «PMID: 10465168»PubMed
36. Yokoyama M, Origasa H, Matsuzaki M, ym. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-8 «PMID: 17398308»PubMed
37. Kwak SM, Myung SK, Lee YJ, ym. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172(9):686-94 «PMID: 22493407»PubMed
38. ORIGIN Trial Investigators, Bosch J, Gerstein HC, ym. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367(4):309-18 «PMID: 22686415»PubMed
39. Rizos EC, Ntzani EE, Bika E, ym. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308(10):1024-33 «PMID: 22968891»PubMed
40. Alexander DD, Miller PE, Van Elswyk ME, ym. A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk. Mayo Clin Proc 2017;92(1):15-29 «PMID: 28062061»PubMed
41. Hu FB, Manson JE. Omega-3 fatty acids and secondary prevention of cardiovascular disease-is it just a fish tale?: comment on “Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease”. Arch Intern Med 2012;172(9):694-6 «PMID: 22493410»PubMed
42. Abdelhamid AS, Brown TJ, Brainard JS, ym. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7(7):CD003177 «PMID: 30019766»PubMed
43. ASCEND Study Collaborative Group, Bowman L, Mafham M, ym. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 2018;379(16):1540-1550 «PMID: 30146932»PubMed
44. Manson JE, Cook NR, Lee IM, ym. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019;380(1):23-32 «PMID: 30415637»PubMed
45. Nicholls SJ, Lincoff AM, Garcia M, ym. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020;324(22):2268-2280 «PMID: 33190147»PubMed
46. Bhatt DL, Steg PG, Miller M, ym. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380(1):11-22 «PMID: 30415628»PubMed
47. Retterstøl K, Rosqvist F. Fat and fatty acids - a scoping review for Nordic Nutrition Recommendations 2023. Food Nutr Res 2024;68(): «PMID: 38327998»PubMed
48. Hooper L, Martin N, Jimoh OF, ym. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 2020;8(8):CD011737 «PMID: 32827219»PubMed
49. Chen Z, Zhou R, Liu X, ym. Effects of Aerobic Exercise on Blood Lipids in People with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life (Basel) 2025;15(2): «PMID: 40003575»PubMed
50. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009;48(1):9-19 «PMID: 19013187»PubMed
51. Lin X, Zhang X, Guo J, ym. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2015;4(7): «PMID: 26116691»PubMed
52. Masmoum MD, Khan S, Usmani WA, ym. The Effectiveness of Exercise in Reducing Cardiovascular Risk Factors Among Adults: A Systematic Review and Meta-Analysis. Cureus 2024;16(9):e68928 «PMID: 39381478»PubMed
53. de Oude KI, Elbers RG, Gerger H, ym. The effect of different resistance exercise training intensities on cardiovascular risk factors: a systematic review and meta-analysis. Eur Heart J Open 2025;5(5):oeaf093 «PMID: 40980719»PubMed
54. Liang L, Peng F, Wang L, ym. Effects of exercise on high-density lipoprotein levels in middle-aged and older individuals: A systematic review and meta-analysis. Medicine (Baltimore) 2025;104(6):e41493 «PMID: 39928779»PubMed
55. Kodama S, Tanaka S, Saito K, ym. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167(10):999-1008 «PMID: 17533202»PubMed
56. Rossebø AB, Pedersen TR, Boman K, ym. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359(13):1343-56 «PMID: 18765433»PubMed
57. Baigent C, Landray MJ, Reith C, ym. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-92 «PMID: 21663949»PubMed
58. Cannon CP, Blazing MA, Giugliano RP, ym. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372(25):2387-97 «PMID: 26039521»PubMed
59. Bach RG, Cannon CP, Giugliano RP, ym. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2019;4(9):846-854 «PMID: 31314050»PubMed
60. Zhan S, Tang M, Liu F, ym. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018;11(11):CD012502 «PMID: 30480766»PubMed
61. Sydhom P, Al-Quraishi B, El-Shawaf M, ym. The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis. BMC Cardiovasc Disord 2024;24(1):660 «PMID: 39567875»PubMed
62. Jun JE, Jeong IK, Ahn KJ, ym. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Eur J Prev Cardiol 2024;31(10):1205-1213 «PMID: 38408362»PubMed
63. Tsujita K, Sugiyama S, Sumida H, ym. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015;66(5):495-507 «PMID: 26227186»PubMed
64. Aung PP, Maxwell HG, Jepson RG, ym. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;2007(4):CD000123 «PMID: 17943736»PubMed
65. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45(4):645-654; discussion 653-4 «PMID: 17398372»PubMed
66. Masson W, Lobo M, Barbagelata L, ym. Effects of lipid-lowering therapy on major adverse limb events in patients with peripheral arterial disease: A meta-analysis of randomized clinical trials. Vascular 2022;30(6):1134-1141 «PMID: 34541946»PubMed
67. Ramos R, García-Gil M, Comas-Cufí M, ym. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J Am Coll Cardiol 2016;67(6):630-640 «PMID: 26868687»PubMed
68. Schmidt AF, Carter JL, Pearce LS, ym. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020;10(10):CD011748 «PMID: 33078867»PubMed
69. Hamayal M, Shahid W, Akhtar CH, ym. Risk of cardiovascular outcomes with bempedoic acid in high-risk statin intolerant patients: a systematic review and meta analysis. Future Cardiol 2024;20(11-12):639-650 «PMID: 39140596»PubMed